JP2023554492A - 共結晶のｃｄｋ阻害剤 - Google Patents

共結晶のｃｄｋ阻害剤 Download PDF

Info

Publication number
JP2023554492A
JP2023554492A JP2023537470A JP2023537470A JP2023554492A JP 2023554492 A JP2023554492 A JP 2023554492A JP 2023537470 A JP2023537470 A JP 2023537470A JP 2023537470 A JP2023537470 A JP 2023537470A JP 2023554492 A JP2023554492 A JP 2023554492A
Authority
JP
Japan
Prior art keywords
formula
fumaric acid
compound
acid compound
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554492A5 (https=
Inventor
ウダイ バート，
ラナディープ ボカリアル，
サンガメッシュ エシュワラッパ バディガー，
クリシュナスワーミ デヴァナタン，
Original Assignee
オーリジーン オンコロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーリジーン オンコロジー リミテッド filed Critical オーリジーン オンコロジー リミテッド
Publication of JP2023554492A publication Critical patent/JP2023554492A/ja
Publication of JP2023554492A5 publication Critical patent/JP2023554492A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023537470A 2020-12-18 2021-12-17 共結晶のｃｄｋ阻害剤 Pending JP2023554492A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (2)

Publication Number Publication Date
JP2023554492A true JP2023554492A (ja) 2023-12-27
JP2023554492A5 JP2023554492A5 (https=) 2024-12-25

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537470A Pending JP2023554492A (ja) 2020-12-18 2021-12-17 共結晶のｃｄｋ阻害剤

Country Status (17)

Country Link
US (1) US20240059669A1 (https=)
EP (1) EP4263534A1 (https=)
JP (1) JP2023554492A (https=)
KR (1) KR20230159363A (https=)
CN (1) CN116685326A (https=)
AU (1) AU2021402415A1 (https=)
CA (1) CA3202198A1 (https=)
CL (1) CL2023001753A1 (https=)
CO (1) CO2023009368A2 (https=)
CR (1) CR20230261A (https=)
DO (1) DOP2023000126A (https=)
EC (1) ECSP23054131A (https=)
IL (1) IL303738A (https=)
MX (1) MX2023007218A (https=)
PE (1) PE20231441A1 (https=)
TW (1) TW202241881A (https=)
WO (1) WO2022130304A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022084930A2 (en) * 2020-10-22 2022-04-28 Aurigene Discovery Technologies Limited Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516917A (ja) * 2015-06-04 2018-06-28 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516917A (ja) * 2015-06-04 2018-06-28 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
山中 宏 他, 光学異性体の分離（季刊 化学総説 NO.6）, JPN6011000511, 1989, pages 2 - 11, ISSN: 0005775202 *
深水啓朗: "Cocrystal（共結晶）に関する話題：概念と実際", ファルマシア, vol. 47, no. 11, JPN6024024181, 2011, pages 1044 - 1048, ISSN: 0005775205 *
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005775203 *
高田 則幸, PHARM TECH JAPAN, vol. 25, no. 12, JPN6013060384, 2009, pages 155 - 166, ISSN: 0005775204 *

Also Published As

Publication number Publication date
CO2023009368A2 (es) 2023-09-29
KR20230159363A (ko) 2023-11-21
ECSP23054131A (es) 2023-09-29
EP4263534A1 (en) 2023-10-25
WO2022130304A1 (en) 2022-06-23
CN116685326A (zh) 2023-09-01
MX2023007218A (es) 2023-07-27
CA3202198A1 (en) 2022-06-23
US20240059669A1 (en) 2024-02-22
CR20230261A (es) 2023-10-04
IL303738A (en) 2023-08-01
TW202241881A (zh) 2022-11-01
PE20231441A1 (es) 2023-09-14
DOP2023000126A (es) 2023-11-30
AU2021402415A1 (en) 2023-07-06
CL2023001753A1 (es) 2024-02-02

Similar Documents

Publication Publication Date Title
JP2023554492A (ja) 共結晶のｃｄｋ阻害剤
JP7829523B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
CN118139855A (zh) 1,4-氧杂氮杂环庚烷衍生物及其用途
JP6097289B2 (ja) セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
AU2014278428B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
TW202140461A (zh) Ras抑制劑及其使用方法
KR102081042B1 (ko) 상피 성장 인자 수용체 키나제 억제제의 고체 형태
CN120548318A (zh) Kras g12d抑制剂和其用途
TW201838966A (zh) 取代的二氫茚－４－甲醯胺及其類似物以及其使用方法
WO2020042995A1 (zh) 一种高活性sting蛋白激动剂化合物
WO2021098859A1 (zh) 氮杂七元环类抑制剂及其制备方法和应用
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
JP2021523208A (ja) ピリミジン誘導体の医薬塩及び障害の処置方法
WO2022188889A1 (zh) 作为parp7抑制剂的化合物
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN112638376B (zh) 取代的四氢环戊二烯并[c]吡咯、取代的二氢吡咯嗪、其类似物和其使用方法
JP2022549353A (ja) プロテインキナーゼｃ（ｐｋｃ）に作用するジテルペノイド化合物
JP2022521413A (ja) Ｓｙｋ阻害剤としての縮合ピラジンの固体形態
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
US20230174545A1 (en) Heterocyclic compounds as bet inhibitors
CA3188173A1 (en) Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same
WO2020064004A1 (zh) 一种mdm2抑制剂，及其制备方法、药物组合物和应用
EA050691B1 (ru) Сокристалл ингибитора cdk
HK40099717A (zh) Cdk抑制剂的共晶体
WO2022143695A1 (zh) 磺酰胺类抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260120